<DOC>
	<DOCNO>NCT00055965</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know one regimen require patient spend time hospital regimen treatment chemotherapy-related side effect . PURPOSE : Randomized phase III trial compare hospitalization rate patient receive gemcitabine combine cisplatin patient receive gemcitabine combine carboplatin unresectable stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Hospitalization Rates Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine Either Cisplatin Carboplatin</brief_title>
	<detailed_description>OBJECTIVES : - Compare rate overnight hospitalization due toxicity ( e.g. , blood transfusion , antibiotic use , obtain relief treatment-related symptom ) patient non-small cell lung cancer treat gemcitabine cisplatin v gemcitabine carboplatin . - Compare need hospitalization chemotherapy administration patient treat regimen . - Compare tumor response rate patient treat regimen . - Compare overall survival patient treat regimen . - Compare relief tumor-related symptom patient treat regimen . - Compare effect Karnofsky performance status patient treat regimen . - Compare toxic effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord stage ( IIIA vs IIIB [ dry ] v IIIB [ wet ] IV ) performance status ( 50-60 % vs 70-100 % ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute cisplatin IV 1-2 hour day 1 8 . - Arm II : Patients receive gemcitabine IV 30 minute day 1 8 carboplatin IV 30-60 minute day 1 . In arm , treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients follow every 2 month 6 month every 3-4 month thereafter . PROJECTED ACCRUAL : A total 400 patient ( 200 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm inoperable nonsmall cell lung cancer Stage IIIA , IIIB , IV Not eligible curative radiotherapy surgery No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 50100 % Life expectancy At least 12 week Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin great 2 time upper limit normal ( ULN ) AST great 2.5 time ULN Alkaline phosphatase great 3 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine great ULN OR Creatinine clearance least 60 mL/min Other Not pregnant nursing Fertile patient must use effective contraception 3 month study completion No active infection No serious systemic disorder would preclude study participation No grade 2 great peripheral neuropathy No significant neurological problem ( e.g. , seizure psychiatric disorder ) No active malignancy within past 5 year except carcinoma situ cervix adequately treat nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior cytotoxic chemotherapy No concurrent chemotherapy 7 day study therapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior radiotherapy No concurrent radiotherapy 7 day study therapy Surgery See Disease Characteristics Other At least 12 week since prior investigational agent No concurrent antitumor therapy No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>